Impact of Formulary Restrictions on Antiepileptic Drug Dispensation Outcomes
- PDF / 1,683,053 Bytes
- 15 Pages / 595.276 x 790.866 pts Page_size
- 60 Downloads / 187 Views
ORIGINAL RESEARCH
Impact of Formulary Restrictions on Antiepileptic Drug Dispensation Outcomes Darshan Mehta
. Matthew Davis . Andrew J. Epstein .
Andrew Lee
Received: April 29, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: The aim of this analysis was to assess the relationship between formulary restrictions and antiepileptic drug (AED) dispensation in patients with focal seizure (FS). Study Design: A retrospective cohort analysis was conducted using data from Symphony Health’s Integrated DataverseÒ (1 April 2015–30 June 2018). Methods: This study included two patient populations: the overall patient population (N = 54,097) and a pediatric population (\ 18 years) (N = 12,610). Cohorts were defined based on approval or rejection of the index AED claim. Study outcomes were prescription life cycle analysis, proportion of patients with dispensation, time to dispensation, and likelihood of successful dispensation. A multivariable Cox proportional hazards model was estimated to Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare.12287858. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40120020-00195-3) contains supplementary material, which is available to authorized users.
study the association between formulary restriction and likelihood of successful AED dispensation. Results: Among patients in the overall population with a rejected claim (n = 9133), 8.0% did not receive any AED and 77.6% received approval for the index AED following an appeal. Among the pediatric patients with a rejected claim (n = 3081), 6.0% did not receive any AED and 81.7% received approval for the index AED after an appeal. In both populations, formulary restrictions were associated with significant delays in index AED dispensation (6.9 and 5.3 days, respectively; P \ 0.0001 for each population), compared to approved AED claims. In the overall and pediatric populations, formulary-related rejections of AEDs were associated with a 35% (hazard ratio [HR] 0.65; 95% confidence interval [CI] 0.64–0.66; P \ 0.0001) and 27% (HR 0.73; 95% CI 0.69–0.76; P \ 0.0001) lower likelihood of successful dispensation of the index AED, respectively. Conclusions: Formulary restrictions of AEDs were associated with significant delays in treatment and significantly lower likelihood of successful AED dispensation in patients with FS.
D. Mehta (&) A. Lee Sunovion Pharmaceuticals Inc., Marlborough, MA, USA e-mail: [email protected]
PLAIN LANGUAGE SUMMARY
M. Davis A. J. Epstein Medicus Economics, LLC, Milton, MA, USA
Formulary restrictions on antiepileptic drugs (AEDs) are adopted by payers in the USA to
Neurol Ther
guide the use of therapies and contain the costs of care. However, formulary restrictions on AEDs are inconsistent with the American Epilepsy Society position statement that indicates patients with epilepsy must have unrestricted access to all AEDs. This retrospective cohort analysis of open-source claims data assessed the effects of f
Data Loading...
